Swiss pharma company Roche (ROG.SW, RHHBY) is warning that its investment into the US could be at risk due to President Trump ...

Bernstein Senior Analyst, US Biopharmaceuticals Courtney ... industry and painted the order as a blow against drugmakers. Eli Lilly (NYSE:LLY) recently announced the impressive results of its ...

Our writer can see the appeal of this recently popular dividend stock from the FTSE 100 index. But will he buy it for his own ...

This writer considers how long it would take an investor to reach a seven-figure sum by maxing out their Stocks and Shares ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Kontra Investments. In this article, we will summarize the bulls’ thesis on NVO.

U.S. tariffs have thrown the market into disarray, leading to massive sell-offs. On the other hand, some investors have ...

A US-China trade deal that includes tariff cuts sent US stock markets soaring. Australia's stock market closed higher in ...

Eli Lilly announced that its obesity therapy Zepbound delivered superior outcomes versus Novo Nordisk’s Wegovy across five ...

Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...

Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week ...

"We think the market reaction was overdone and are thus reiterating our OP [Outperform] rating on LLY," Leerink Partners analyst David Risinger wrote in a note to clients Friday. Risinger also lowered ...

demonstrating its operational efficiency.Want deeper insights? InvestingPro subscribers have access to 14 additional ProTips and comprehensive financial metrics for Eli Lilly, including detailed ...